United States Intrathecal Drugs for Post-Operative Pain Management Market Insights Forecasts to 2033

• The U.S. Intrathecal Drugs for Post-Operative Pain Management Market Size was valued at USD 6.97 Million in 2023.
• The Market is growing at a CAGR of 4.48% from 2023 to 2033
• The U.S. Intrathecal Drugs for Post-Operative Pain Management Market Size is Expected to Reach USD 10.80 Million by 2033

The U.S. Intrathecal Drugs for Post-Operative Pain Management Market is Anticipated to Exceed USD 10.80 Million by 2033, growing at a CAGR of 4.48% from 2023 to 2033.

Market Overview

The intrathecal drugs used for post-operative pain management are morphine and bupivacaine, among others, and these are normally administered before surgery in the spinal cord area. More and more patients, the country has been witnessing, are undergoing transplants, coronary artery bypass, transurethral resection of prostate (TURP), hip arthroplasty, knee arthroplasty, organ transplants, and similar surgical procedures, which has ensured the growth of the U.S. Intrathecal Drugs market. The American Academy of Orthopaedic Surgeons estimates that in the United States, each year, there are about 790,000 total knee replacements and 450,000 total hip replacements. AnMed statistics have shown the number as of November 2023. Currently, only the intrathecal formulations of morphine, baclofen, and ziconotide are available under FDA approval. Drugs such as bupivacaine, hydromorphone, clonidine, among others have also been used, albeit off-label. The increase in the number of surgical procedures such as hip replacement, coronary artery bypass, and spinal surgeries has been driving the country's demand for these drugs. This is supplemented by increasing awareness regarding the efficacy of intrathecal drugs such as morphine and bupivacaine in post-operative pain management.

Report Coverage

This research report categorizes the market for the US intrathecal drugs for post-operative pain management market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States intrathecal drugs for post-operative pain management market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the U.S. intrathecal drugs for post-operative pain management market.

Driving Factors

These surgeries require intrathecal drugs in the post-operative management for pain relief. for instance, benign prostatic hyperplasia, the final treatment is surgery where the blocking adenoma of the prostate can be displaced or removed. With the rising number of chronic diseases, the requirements for intrathecal drugs, to be utilized postoperatively in managing pain, have increased. For instance, colorectal cancer is one of the most occurring cancers by incidence in the U.S. It is also the second leading cause of cancer-related deaths in the country. It is estimated that colorectal cancer would cause 53,000 deaths in the U.S. with an annual incidence of about 106,590 cases in 2024 according to the American Cancer Society.

Restraining Factors

Intrathecal drugs, on the other hand, contain some risk factors that have rendered them less chosen for post-operative pain control.

Market Segmentation

The US intrathecal drugs for post-operative pain management market share are classified into drug class and end-user.

• The morphine segment is expected to hold a significant market share through the forecast period.

The United States intrathecal drugs for post-operative pain management market is segmented by drug class into morphine, baclofen, ziconotide, bupivacaine, hydromorphone, clonidine, fentanyl, sufentanil, and others. Among these, the morphine segment is expected to hold a significant market share through the forecast period. This dominance is attributed to the longer half-life of the drug class. For instance, as cited by Elsevier Ltd. in a June 2023 publication, for as little as 0.1-0.15 mg of intrathecal morphine post-operative analgesia could be secured for up to 20-48 hours.

• The hospitals segment is expected to dominate the US market during the projected period.

Based on the end-user, the United States intrathecal drugs for post-operative pain management market is divided into hospitals, ambulatory surgical centers, pain clinics, and others. Among these, the hospitals segment is expected to dominate the US intrathecal drugs for post-operative pain management market during the projected period. This is attributed to the more people go to the hospital for efficient treatment. As an instance, according to statistics from the American Hospital Association, in 2022, around 33.6 million people experienced admission into a hospital in the U.S. The process is up by 1.0% as compared with 2020.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States intrathecal drugs for post-operative pain management market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Piramal Pharma Limited (Piramal Group)
• Baxter
• Hikma Pharmaceuticals PLC
• Viatris Inc.
• Pfizer Inc.
• Amneal Pharmaceuticals LLC
• Fresenius SE & Co. KGaA
• TerSera Therapeutics LLC.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, TerSera Therapeutics LLC recently presented at the American Society of Pain and Neuroscience Annual Conference. The company was provided a great opportunity to share knowledge about the management of pain therapies and to explore the possibility of cooperative partnerships in neuromodulation with healthcare professionals.

Market Segment

This study forecasts revenue at U.S., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United States intrathecal drugs for post-operative pain management market based on the below-mentioned segments:

United States Intrathecal Drugs for Post-Operative Pain Management Market, By Drug Class

• Morphine
• Baclofen
• Ziconotide
• Bupivacaine
• Hydromorphone
• Clonidine
• Fentanyl
• Sufentanil
• Others

United States Intrathecal Drugs for Post-Operative Pain Management Market, By End-User

• Hospitals
• Ambulatory Surgical Centers
• Pain Clinics
• Others